Literature DB >> 33604753

Characterization of microbiota in acute leukemia patients following successful remission induction chemotherapy without antimicrobial prophylaxis.

Zhenglei Shen1, Xuezhong Gu2, Honghua Cao1, Wenwen Mao3, Linlin Yang4, Min He1, Rui Zhang1, Yeying Zhou1, Kunmei Liu1, Lilan Wang1, Lianqing Liu1, Jingxing Yu5, Liefen Yin6.   

Abstract

PURPOSE: In the present study, we characterized the microbiomes of acute leukemia (AL) patients who achieved complete remission following remission induction chemotherapy (RIC) as outpatients, but who did not receive antimicrobials to treat or prevent febrile neutropenia.
METHODS: Saliva and stool samples from 9 patients with acute myeloid leukemia, 11 patients with acute lymphoblastic leukemia, and 5 healthy controls were subjected to 16S ribosomal RNA sequencing at baseline and at 3 months following RIC. Only patients who achieved remission at 3 months post-treatment were included. We excluded anyone who used antimicrobials within 2 months of enrollment or at any time during the study period.
RESULTS: At baseline, the relative abundances of species of Prevotella maculosa (P=0.001), Megasphaera micronuciformis (P=0.014), Roseburia inulinivorans (P=0.021), and Bacteroides uniformis (P=0.004) in saliva and Prevotella copri (P=0.002) in the stools of controls were significantly higher than in AL patients. Following RIC, the relative abundances of Eubacterium sp. oral clone DO008 (P=0.012), Leptotrichia sp. oral clone IK040 (P=0.002), Oribacterium sp. oral taxon 108 (P=0.029), Megasphaera micronuciformis (P=0.016), TM7 phylum sp. oral clone DR034 (P<0.001), Roseburia inulinivorans (P=0.034), Actinomyces odontolyticus (P=0.014), Leptotrichia buccalis (P=0.005), and Prevotella melaninogenica (P=0.046) in saliva and Lactobacillus fermentum (P=0.046), Coprococcus catus (P=0.050), butyrate-producing bacterium SS3/4 (P=0.013), and Bacteroides coprocola (P=0.027) in the stools of AL patients were significantly greater than in controls.
CONCLUSION: Following RIC, several taxa are changed in stool and salvia samples of AL patients. Our results warrant future large-scale multicenter studies to examine whether the microbiota might have an effect on clinical outcomes of AL patients.

Entities:  

Keywords:  Febrile neutropenia; Induction chemotherapy; Leukemia; Microbiome; Microbiota; Saliva

Year:  2021        PMID: 33604753     DOI: 10.1007/s10123-021-00163-3

Source DB:  PubMed          Journal:  Int Microbiol        ISSN: 1139-6709            Impact factor:   2.479


  10 in total

Review 1.  Gut Microbiota, Inflammation, and Colorectal Cancer.

Authors:  Caitlin A Brennan; Wendy S Garrett
Journal:  Annu Rev Microbiol       Date:  2016-09-08       Impact factor: 15.500

2.  Studies on Paragonimus and paragonimiasis in the Philippines. 3. Prevalence and treatment of human paragonimiasis with bithionol in Jaro, Leyte, Philippines.

Authors:  B D Cabrera; P M Fevidal
Journal:  Southeast Asian J Trop Med Public Health       Date:  1974-03       Impact factor: 0.267

Review 3.  The microbiome of the critically ill patient.

Authors:  Kevan Akrami; Daniel A Sweeney
Journal:  Curr Opin Crit Care       Date:  2018-02       Impact factor: 3.687

4.  Intestinal mucosal dysfunction and infection during remission-induction therapy for acute myeloid leukaemia.

Authors:  E J Bow; J B Meddings
Journal:  Leukemia       Date:  2006-11-02       Impact factor: 11.528

5.  Intestinal inflammation targets cancer-inducing activity of the microbiota.

Authors:  Janelle C Arthur; Ernesto Perez-Chanona; Marcus Mühlbauer; Sarah Tomkovich; Joshua M Uronis; Ting-Jia Fan; Barry J Campbell; Turki Abujamel; Belgin Dogan; Arlin B Rogers; Jonathan M Rhodes; Alain Stintzi; Kenneth W Simpson; Jonathan J Hansen; Temitope O Keku; Anthony A Fodor; Christian Jobin
Journal:  Science       Date:  2012-08-16       Impact factor: 47.728

6.  Chemotherapy treatment in pediatric patients with acute myeloid leukemia receiving antimicrobial prophylaxis leads to a relative increase of colonization with potentially pathogenic bacteria in the gut.

Authors:  Michel J van Vliet; Wim J E Tissing; Catharina A J Dun; Nico E L Meessen; Willem A Kamps; Eveline S J M de Bont; Hermie J M Harmsen
Journal:  Clin Infect Dis       Date:  2009-07-15       Impact factor: 9.079

7.  NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer.

Authors:  Aurélie Couturier-Maillard; Thomas Secher; Ateequr Rehman; Sylvain Normand; Adèle De Arcangelis; Robert Haesler; Ludovic Huot; Teddy Grandjean; Aude Bressenot; Anne Delanoye-Crespin; Olivier Gaillot; Stefan Schreiber; Yves Lemoine; Bernhard Ryffel; David Hot; Gabriel Nùñez; Grace Chen; Philip Rosenstiel; Mathias Chamaillard
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

8.  The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia.

Authors:  Jessica R Galloway-Peña; Daniel P Smith; Pranoti Sahasrabhojane; Nadim J Ajami; W Duncan Wadsworth; Naval G Daver; Roy F Chemaly; Lisa Marsh; Shashank S Ghantoji; Naveen Pemmaraju; Guillermo Garcia-Manero; Katayoun Rezvani; Amin M Alousi; Jennifer A Wargo; Elizabeth J Shpall; Phillip A Futreal; Michele Guindani; Joseph F Petrosino; Dimitrios P Kontoyiannis; Samuel A Shelburne
Journal:  Cancer       Date:  2016-05-03       Impact factor: 6.860

9.  Gut microbiota-derived propionate reduces cancer cell proliferation in the liver.

Authors:  L B Bindels; P Porporato; E M Dewulf; J Verrax; A M Neyrinck; J C Martin; K P Scott; P Buc Calderon; O Feron; G G Muccioli; P Sonveaux; P D Cani; N M Delzenne
Journal:  Br J Cancer       Date:  2012-09-13       Impact factor: 7.640

10.  Synbiotic approach restores intestinal homeostasis and prolongs survival in leukaemic mice with cachexia.

Authors:  Laure B Bindels; Audrey M Neyrinck; Sandrine P Claus; Caroline I Le Roy; Corinne Grangette; Bruno Pot; Inés Martinez; Jens Walter; Patrice D Cani; Nathalie M Delzenne
Journal:  ISME J       Date:  2015-11-27       Impact factor: 10.302

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.